533 related articles for article (PubMed ID: 20349060)
21. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
23. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
24. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
27. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
[TBL] [Abstract][Full Text] [Related]
28. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
29. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
30. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
31. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
32. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
33. [PAD regimen for relapsed or refractory patients with multiple myeloma].
Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
[TBL] [Abstract][Full Text] [Related]
36. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
[TBL] [Abstract][Full Text] [Related]
37. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
38. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
